{"id":69016,"date":"2026-06-29T15:03:21","date_gmt":"2026-06-29T07:03:21","guid":{"rendered":"https:\/\/flcube.com\/?p=69016"},"modified":"2026-06-29T15:03:22","modified_gmt":"2026-06-29T07:03:22","slug":"nhsa-advances-record-674-drugs-in-2026-insurance-catalog-review-with-92-preliminary-pass-rate","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=69016","title":{"rendered":"NHSA Advances Record 674 Drugs in 2026 Insurance Catalog Review with 92% Preliminary Pass Rate"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">China&#8217;s <strong>National Healthcare Security Administration (NHSA)<\/strong> released preliminary formal review results for the <strong>2026 National Drug Catalog adjustment<\/strong>, advancing a record <strong>674 generic drug names<\/strong> from <strong>818 submission packages<\/strong> received between June 1\u201310, 2026. The process covers both the <strong>National Catalog of Drugs for Basic Medical Insurance, Maternity Insurance, and Work-Related Injury Insurance<\/strong> and the <strong>Commercial Insurance Innovative Drug Catalog<\/strong>.<\/p>\n\n\n\n<h2 id=\"h-submission-amp-review-statistics\" class=\"wp-block-heading\">Submission &amp; Review Statistics<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Category<\/th><th>Submitted<\/th><th>Passed<\/th><th>Pass Rate<\/th><\/tr><\/thead><tbody><tr><td><strong>Out-of-list applications<\/strong><\/td><td>375<\/td><td>334<\/td><td>89%<\/td><\/tr><tr><td><strong>Within-catalog applications<\/strong><\/td><td>229<\/td><td>223<\/td><td>97%<\/td><\/tr><tr><td><strong>Commercial insurance catalog (external)<\/strong><\/td><td>57<\/td><td>53<\/td><td>93%<\/td><\/tr><tr><td><strong>Commercial insurance catalog (internal)<\/strong><\/td><td>1<\/td><td>1<\/td><td>100%<\/td><\/tr><tr><td><strong>Overall (excluding pre-submitted)<\/strong><\/td><td>662<\/td><td>611<\/td><td><strong>92%<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-key-metrics-amp-year-over-year-comparison\" class=\"wp-block-heading\">Key Metrics &amp; Year-over-Year Comparison<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Metric<\/th><th>2026<\/th><th>2025<\/th><th>Change<\/th><\/tr><\/thead><tbody><tr><td><strong>Total submission packages<\/strong><\/td><td>818<\/td><td>718<\/td><td><strong>+100<\/strong><\/td><\/tr><tr><td><strong>Generic drug names<\/strong><\/td><td>674<\/td><td>633<\/td><td><strong>+41<\/strong><\/td><\/tr><tr><td><strong>Preliminary pass rate<\/strong><\/td><td>92%<\/td><td>84%<\/td><td><strong>+8 ppt<\/strong><\/td><\/tr><tr><td><strong>New drugs (past 5 years)<\/strong><\/td><td>343<\/td><td>N\/A<\/td><td>New tracking<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-pre-submission-activity-summary\" class=\"wp-block-heading\">Pre-Submission Activity Summary<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>49 generic names<\/strong> pre-submitted for out-of-list inclusion (including 2 with simultaneous new indication applications)<\/li>\n\n\n\n<li><strong>11 generic names<\/strong> within basic catalog pre-submitted for new indications<\/li>\n\n\n\n<li><strong>4 generic names<\/strong> pre-submitted for inclusion outside commercial insurance innovative drug catalog<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-strategic-implications\" class=\"wp-block-heading\">Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Market Access Acceleration:<\/strong> The 92% preliminary pass rate\u2014up 8 percentage points from 2025\u2014indicates NHSA&#8217;s streamlined evaluation process while maintaining quality standards<\/li>\n\n\n\n<li><strong>Innovation Focus:<\/strong> Majority of submissions represent new drugs, with 343 newly approved generic drugs from the past five years submitted under Criterion 1 (outside catalog)<\/li>\n\n\n\n<li><strong>Industry Confidence:<\/strong> Record submission volume reflects growing pharmaceutical industry confidence in China&#8217;s national insurance reimbursement framework<\/li>\n\n\n\n<li><strong>Patient Impact:<\/strong> Successful catalog inclusion will expand patient access to innovative therapies across basic medical, maternity, and work-related injury insurance coverage<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">The preliminary clearance sets the stage for the next phase of price negotiations and final inclusion decisions, positioning manufacturers for competitive advantage in China&#8217;s healthcare market.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking information regarding regulatory processes and market expectations. Actual outcomes may vary based on final NHSA decisions, pricing negotiations, and market dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>China&#8217;s National Healthcare Security Administration (NHSA) released preliminary formal review results for the 2026 National&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[4],"tags":[],"class_list":["post-69016","post","type-post","status-publish","format-standard","hentry","category-policy-regulatory"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.9) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>NHSA Advances Record 674 Drugs in 2026 Insurance Catalog Review with 92% Preliminary Pass Rate - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China&#039;s National Healthcare Security Administration (NHSA) released preliminary formal review results for the 2026 National Drug Catalog adjustment, advancing a record 674 generic drug names from 818 submission packages received between June 1\u201310, 2026. The process covers both the National Catalog of Drugs for Basic Medical Insurance, Maternity Insurance, and Work-Related Injury Insurance and the Commercial Insurance Innovative Drug Catalog.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=69016\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"NHSA Advances Record 674 Drugs in 2026 Insurance Catalog Review with 92% Preliminary Pass Rate\" \/>\n<meta property=\"og:description\" content=\"China&#039;s National Healthcare Security Administration (NHSA) released preliminary formal review results for the 2026 National Drug Catalog adjustment, advancing a record 674 generic drug names from 818 submission packages received between June 1\u201310, 2026. The process covers both the National Catalog of Drugs for Basic Medical Insurance, Maternity Insurance, and Work-Related Injury Insurance and the Commercial Insurance Innovative Drug Catalog.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=69016\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-29T07:03:21+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-29T07:03:22+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69016#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69016\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"NHSA Advances Record 674 Drugs in 2026 Insurance Catalog Review with 92% Preliminary Pass Rate\",\"datePublished\":\"2026-06-29T07:03:21+00:00\",\"dateModified\":\"2026-06-29T07:03:22+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69016\"},\"wordCount\":294,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"articleSection\":[\"Policy \\\/ Regulatory\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=69016#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69016\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=69016\",\"name\":\"NHSA Advances Record 674 Drugs in 2026 Insurance Catalog Review with 92% Preliminary Pass Rate - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-06-29T07:03:21+00:00\",\"dateModified\":\"2026-06-29T07:03:22+00:00\",\"description\":\"China's National Healthcare Security Administration (NHSA) released preliminary formal review results for the 2026 National Drug Catalog adjustment, advancing a record 674 generic drug names from 818 submission packages received between June 1\u201310, 2026. The process covers both the National Catalog of Drugs for Basic Medical Insurance, Maternity Insurance, and Work-Related Injury Insurance and the Commercial Insurance Innovative Drug Catalog.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69016#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=69016\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69016#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"NHSA Advances Record 674 Drugs in 2026 Insurance Catalog Review with 92% Preliminary Pass Rate\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"NHSA Advances Record 674 Drugs in 2026 Insurance Catalog Review with 92% Preliminary Pass Rate - Insight, China&#039;s Pharmaceutical Industry","description":"China's National Healthcare Security Administration (NHSA) released preliminary formal review results for the 2026 National Drug Catalog adjustment, advancing a record 674 generic drug names from 818 submission packages received between June 1\u201310, 2026. The process covers both the National Catalog of Drugs for Basic Medical Insurance, Maternity Insurance, and Work-Related Injury Insurance and the Commercial Insurance Innovative Drug Catalog.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=69016","og_locale":"en_US","og_type":"article","og_title":"NHSA Advances Record 674 Drugs in 2026 Insurance Catalog Review with 92% Preliminary Pass Rate","og_description":"China's National Healthcare Security Administration (NHSA) released preliminary formal review results for the 2026 National Drug Catalog adjustment, advancing a record 674 generic drug names from 818 submission packages received between June 1\u201310, 2026. The process covers both the National Catalog of Drugs for Basic Medical Insurance, Maternity Insurance, and Work-Related Injury Insurance and the Commercial Insurance Innovative Drug Catalog.","og_url":"https:\/\/flcube.com\/?p=69016","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-06-29T07:03:21+00:00","article_modified_time":"2026-06-29T07:03:22+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=69016#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=69016"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"NHSA Advances Record 674 Drugs in 2026 Insurance Catalog Review with 92% Preliminary Pass Rate","datePublished":"2026-06-29T07:03:21+00:00","dateModified":"2026-06-29T07:03:22+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=69016"},"wordCount":294,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"articleSection":["Policy \/ Regulatory"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=69016#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=69016","url":"https:\/\/flcube.com\/?p=69016","name":"NHSA Advances Record 674 Drugs in 2026 Insurance Catalog Review with 92% Preliminary Pass Rate - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-06-29T07:03:21+00:00","dateModified":"2026-06-29T07:03:22+00:00","description":"China's National Healthcare Security Administration (NHSA) released preliminary formal review results for the 2026 National Drug Catalog adjustment, advancing a record 674 generic drug names from 818 submission packages received between June 1\u201310, 2026. The process covers both the National Catalog of Drugs for Basic Medical Insurance, Maternity Insurance, and Work-Related Injury Insurance and the Commercial Insurance Innovative Drug Catalog.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=69016#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=69016"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=69016#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"NHSA Advances Record 674 Drugs in 2026 Insurance Catalog Review with 92% Preliminary Pass Rate"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69016","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=69016"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69016\/revisions"}],"predecessor-version":[{"id":69017,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69016\/revisions\/69017"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=69016"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=69016"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=69016"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}